Omeros Corporation (NASDAQ:OMER – Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $11.64 and traded as high as $12.00. Omeros shares last traded at $11.65, with a volume of 1,168,362 shares.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on OMER shares. Weiss Ratings upgraded shares of Omeros from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, May 14th. Zacks Research raised shares of Omeros from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 2nd. Wall Street Zen lowered shares of Omeros from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. D. Boral Capital reissued a “buy” rating and issued a $36.00 price objective on shares of Omeros in a research report on Tuesday, April 21st. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Omeros in a research report on Thursday, May 14th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $40.33.
Omeros Stock Up 1.7%
Omeros (NASDAQ:OMER – Get Free Report) last announced its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.16. The firm had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $4.19 million. On average, sell-side analysts anticipate that Omeros Corporation will post -0.94 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in OMER. State of Wyoming bought a new position in Omeros during the 4th quarter valued at $25,000. B. Riley Wealth Advisors Inc. bought a new position in Omeros during the 2nd quarter valued at $32,000. Caitong International Asset Management Co. Ltd bought a new position in Omeros during the 4th quarter valued at $33,000. Assetmark Inc. bought a new position in Omeros during the 1st quarter valued at $38,000. Finally, Tower Research Capital LLC TRC boosted its stake in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 11,971 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.
About Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Stories
- Five stocks we like better than Omeros
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.
